Children below the age of 14 years (due to the high doses of the active ingredients)
To date, incretin-based approaches for obesity management appear as the most promising and rapidly developing (Supplementary Table 1), with innovations such as once-weekly (OW) injectable triple GIPR/GCGR/GLP-1R agonist retatrutide (LY3437943), cagrilintide (long-acting amylin analogue)/semaglutide 2.4 mg (CagriSema) combination, GCGR/GLP-1R dual agonists, high-dose oral semaglutide, and oral non-peptide GLP-1 receptor agonist orforglipron, with relevant implications in terms of patients compliance and environmental sustainability
Further cause-consequence evidence could be seen in BPC 157-treated rats with high intra-abdominal pressures, as treatment largely abrogated both arterial and venous thrombosis
In simple terms, AOD-9604 may support weight management by: Encouraging the body to break down stored fat Increasing fat oxidation for energy Limiting the development of new fat cells Some research has also suggested that the peptide may influence cartilage repair and joint health, although this area requires further investigation
